Top Page
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
(1558)
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (1558) vs. iShares MSCI Hong Kong ETF (EWH)
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Business Overview & Revenue Model
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.72B | 6.29B | 3.74B | 913.79M | 2.35B |
| Gross Profit | 2.79B | 4.99B | 2.85B | 483.70M | 2.00B |
| EBITDA | 1.05B | 2.75B | 691.48M | -206.55M | 950.24M |
| Net Income | 482.71M | 1.99B | 76.60M | -587.65M | 839.46M |
Balance Sheet | |||||
| Total Assets | 12.43B | 12.74B | 11.89B | 10.54B | 9.56B |
| Cash, Cash Equivalents and Short-Term Investments | 1.41B | 1.69B | 1.21B | 1.13B | 2.04B |
| Total Debt | 2.23B | 2.61B | 3.82B | 3.19B | 3.01B |
| Total Liabilities | 3.92B | 4.81B | 5.82B | 4.52B | 4.46B |
| Stockholders Equity | 8.51B | 7.94B | 5.88B | 5.81B | 4.89B |
Cash Flow | |||||
| Free Cash Flow | -1.09B | 1.08B | 1.13B | -1.02B | 305.33M |
| Operating Cash Flow | 89.42M | 1.67B | 1.70B | -662.51M | 1.30B |
| Investing Cash Flow | 88.26M | 554.57M | -1.12B | -439.11M | -2.09B |
| Financing Cash Flow | -448.31M | -1.48B | -787.03M | 187.48M | 64.63M |
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Technical Analysis
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | €11.23B | 11.21 | 23.28% | 4.45% | 12.70% | 9.91% | |
74 Outperform | HK$3.12B | 10.83 | 12.47% | 3.96% | 7.43% | 21.88% | |
74 Outperform | HK$6.15B | 6.75 | 11.61% | 6.20% | -18.09% | -15.08% | |
70 Outperform | HK$10.69B | 11.58 | 8.89% | 3.74% | 4.91% | -11.80% | |
65 Neutral | HK$12.65B | 26.73 | 5.88% | 10.31% | -42.02% | -76.29% | |
58 Neutral | $11.43B | 195.69 | 0.25% | 4.53% | -10.72% | -95.88% | |
51 Neutral | $7.38B | 0.36 | -65.68% | 2.37% | 16.55% | 0.39% |
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Corporate Events
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced the withdrawal of its H Shares from the Hong Kong Stock Exchange, effective from August 5, 2025. This move is part of a merger with Sunshine Lake Pharma Co., Ltd., where a share exchange will occur, allowing shareholders to exchange their H Shares for Offeror H Shares at a specified ratio. The delisting and share exchange are significant steps in the merger process, impacting the company’s market presence and shareholder structure.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced the payment of a special dividend to its shareholders, excluding the Offeror and its subsidiaries, scheduled for October 31, 2025. The company will adhere to the PRC Tax Law by withholding and paying the required income tax on dividends distributed to overseas non-resident enterprise and individual H Shareholders, with specific arrangements based on the shareholders’ country of domicile.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced an update to its special cash dividend for shareholders, declaring a dividend of HKD 1.5 per share. The payment date has been set for October 31, 2025, with specific details regarding withholding tax rates for non-resident shareholders. This announcement reflects the company’s commitment to returning value to its shareholders, potentially enhancing its attractiveness to investors and impacting its market position.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Co., Ltd. have announced the results of the exercise of the right of dissenting shareholders in relation to their merger. During the designated declaration period, no dissenting shareholders exercised their rights, indicating a smooth progression towards the merger by absorption. This merger involves the exchange and cancellation of securities between the two companies, which are both incorporated in China. The merger is subject to Hong Kong disclosure requirements and may present challenges for U.S. shareholders in terms of rights enforcement due to jurisdictional differences.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced the results of its Extraordinary General Meeting (EGM) and H Shareholders’ Class Meeting, where all proposed resolutions were passed. This development is part of a proposed conditional privatization by Sunshine Lake Pharma Co., Ltd. through a merger by absorption, which includes the withdrawal of the company’s listing and a proposed special dividend. The approval of these resolutions marks a significant step in the company’s strategic reorganization, potentially impacting its market presence and shareholder value.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced a special cash dividend of HKD 1.5 per share, with shareholders’ approval set for July 21, 2025. This announcement may impact the company’s financial distribution strategy and provide returns to shareholders, reflecting the company’s current financial health and commitment to shareholder value.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is undergoing a proposed conditional privatization by Sunshine Lake Pharma Co., Ltd. through a merger by absorption. This process involves the withdrawal of the company’s listing and the dispatch of a composite document to shareholders. The composite document, which includes details about the merger, listing, and recommendations from the Independent Board Committee and the Independent Financial Adviser, will be sent to shareholders on June 30, 2025. This move is significant as it marks a strategic shift in the company’s operations, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced an extraordinary general meeting (EGM) to be held on July 21, 2025, to discuss and approve a merger agreement with Sunshine Lake Pharma Co., Ltd. The meeting will also consider the approval of a special dividend of HK$1.50 per share for shareholders, excluding the offeror and its subsidiaries. The merger and dividend decisions are significant for the company’s strategic direction and may impact shareholder value.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced an H shareholders’ class meeting scheduled for July 21, 2025, to consider a special resolution regarding a merger agreement with Sunshine Lake Pharma Co., Ltd. The approval of this merger is contingent on a 75% affirmative vote from independent H shareholders, with less than 10% opposition. This meeting is crucial for the company’s strategic direction and could significantly impact its market position and stakeholder interests.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced the fulfillment of all pre-conditions for its proposed conditional privatization through a merger by absorption with Sunshine Lake Pharma Co., Ltd. This development marks a significant step forward in the merger process, with the Stock Exchange approving the listing of the Offeror H Shares, which are to be issued as consideration for the cancellation of the Share Exchange H Shares under the merger. The completion of these pre-conditions indicates progress in the merger, potentially impacting the company’s market positioning and stakeholder interests.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Co., Ltd. have announced the proposed pre-conditional privatization of YiChang HEC ChangJiang Pharmaceutical by way of a merger. The merger process has seen partial fulfillment of pre-conditions, with approvals from the CSRC completed, while approval from the Stock Exchange’s Listing Committee is still pending. Additionally, the long-stop date for fulfilling these conditions has been extended, indicating ongoing efforts to finalize the merger.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced the fulfilment of certain pre-conditions related to its proposed merger with Sunshine Lake Pharma Co., Ltd. The merger, structured as a merger by absorption, has met Pre-Conditions (1) and (3), involving necessary governmental approvals and shareholder approval. However, Pre-Condition (2), which pertains to the listing and vetting process with the Stock Exchange and SFC, is still pending. The completion of this merger is expected to impact the company’s operations and market positioning, with further announcements to be made as developments occur.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. successfully held its Annual General Meeting (AGM) on May 29, 2025, where all proposed resolutions were approved by shareholders. The resolutions included the approval of the company’s financial statements and reports for the year ended December 31, 2024, and the re-appointment of KPMG as the company’s auditor. The approval of these resolutions reflects strong shareholder support and positions the company for continued stability and growth.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Co., Ltd. have announced a monthly update on their proposed pre-conditional privatization merger. The merger is progressing, with the NDRC approval obtained and the MoC approval deemed unnecessary. However, approvals from SAFE and the Stock Exchange are still pending, leaving some pre-conditions unfulfilled. The merger’s completion is contingent upon these approvals and other conditions, impacting the company’s future operations and market positioning.